Saint Luke's Newsroom

After feeling chest pain, Gina Cusimano's suspected asthma turned out to be something much more serious. KMBC talked to Dr. Cho about how he removed a blood clot in her lung with the FlowTriever device.

A new study championed by Saint Luke's, called DEFINE-HF, was recently presented at the Heart Failure Society of America annual meeting. tctMD breaks down this groundbreaking study of the new treatment option with study chair Mikhail Kosiborod, MD.

After receiving a heart transplant at Saint Luke's Mid America Heart Institute, John Shultz learned of his 24-year-old donor. FOX4 tells the story of how the generous donation brought two families together.

Trial findings shared at HFSA’s Annual Scientific Meeting Late-Breaking Clinical Trial Session

Mikhail Kosiborod, MD, director of Cardiometabolic Research at Saint Luke’s Mid America Heart Institute, discussed where the clinical understanding of sodium-glucose co-transporter-2 inhibitors—as well as GLP-1 agonists—are stationed headed into the new dapagliflozin data.

Cardiology fellow Krishna Patel, MD, presented an update on her research into patient-friendly reporting of cardiac imaging results at the ASNC's 24th Annual Scientific Session 2019 session, “Machine Learning in SPECT MPI Applications."

Nearly 4,000 runners gathered to compete in the 2019 Plaza 10K to benefit Saint Luke's Home Care and Hospice.

DEFINE-HF was not only the first multi-center randomized placebo-controlled clinical trial that Saint Luke’s developed, coordinated, and implemented in its entirety, but the first significant effort to look at what effect dapagliflozin, a drug initially created for the treatment of diabetes, was going to have in patients who also have heart failure.